Evidence map›Paper›PMID 29401749›Full record

ArticleMolecules (Basel, Switzerland)2018

The Fungal Metabolite Eurochevalierine, a Sequiterpene Alkaloid, Displays Anti-Cancer Properties through Selective Sirtuin 1/2 Inhibition.

Michael Schnekenburger, Véronique Mathieu, Florence Lefranc, Jun Young Jang, Marco Masi, Anake Kijjoa, Antonio Evidente, Hyun-Jung Kim, Robert Kiss, Mario Dicato and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Biosynthesis of Terpenoid-Pyrrolobenzoxazine Hybrid Natural Product CJ-12662.Angewandte Chemie (International ed. in English) · 2022
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Michael SchnekenburgerLaboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg. michael.schnekenburger@lbmcc.lu.ORCID 0000-0003-0550-9538
Véronique MathieuDepartment of Pharmacotherapy and Pharmaceutics, Faculté de Pharmacie, Université Libre de Bruxelles, Boulevard du Triomphe, 1050 Brussels, Belgium. vemathie@ulb.ac.be.
Florence LefrancService de Neurochirurgie, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium. florence.lefranc@erasme.ulb.ac.be.
Jun Young JangDepartment of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro Gwanak-gu, Seoul 08826, Korea. nosvc4@snu.ac.kr.
Marco MasiDipartimento di Scienze Chimiche, Università di Napoli Federico II, Via Cintia 4, 80126 Napoli, Italy. marco.masi@unina.it.ORCID 0000-0003-0609-8902
Anake KijjoaInstituto de Ciências Biomédicas de Abel Salazar (ICBAS) and CIIMAR, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal. ankijjoa@icbas.up.pt.ORCID 0000-0002-3321-1061
Antonio EvidenteDipartimento di Scienze Chimiche, Università di Napoli Federico II, Via Cintia 4, 80126 Napoli, Italy. evidente@unina.it.
Hyun-Jung KimCollege of Pharmacy, Chung-Ang University, 84 Heukseok-ro Dongjak-gu, Seoul 06974, Korea. hyunjungkim@cau.ac.kr.
Robert KissRetired - previously Director of Research at the Fonds National de la Recherche Scientifique (FRS-FNRS; Belgium). rkiss2012@gmail.com.
Mario DicatoLaboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg. rkiss2012@gmail.com.
Byung Woo HanDepartment of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro Gwanak-gu, Seoul 08826, Korea. bwhan@snu.ac.kr.ORCID 0000-0001-7571-3791
Marc DiederichDepartment of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro Gwanak-gu, Seoul 08826, Korea. marcdiederich@snu.ac.kr.ORCID 0000-0003-0115-4725
Seoul National University · KRHôpital Kirchberg · LUUniversité Libre de Bruxelles · BEUniversity of Naples Federico II · ITChung-Ang University · KRFund for Scientific Research · BEUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NAD⁺-dependent histone deacetylases (sirtuins) are implicated in cellular processes such as proliferation, DNA repair, and apoptosis by regulating gene expression and the functions of numerous proteins. Due to their key role in cells, the discovery of small molecule sirtuin modulators has been of significant interest for diverse therapeutic applications. In particular, it has been shown that inhibition of sirtuin 1 and 2 activities is beneficial for cancer treatment. Here, we demonstrate that the fungal metabolite eurochevalierine from the fungus

Indexed as

Gene Expression Regulation, NeoplasticProtein Processing, Post-TranslationalAcetylationAlkaloidsAntineoplastic AgentsBinding SitesHistone Deacetylase InhibitorsHistonesHumansMolecular Docking SimulationNeosartoryaProtein BindingProtein Conformation, alpha-HelicalProtein Conformation, beta-StrandProtein Interaction Domains and MotifsSesquiterpenesAlkaloidsAntineoplastic AgentsHistone Deacetylase InhibitorsHistonesSesquiterpenesSIRT1 protein, humanSIRT2 protein, humanSIRT3 protein, humanSirtuin 1Sirtuin 2Sirtuin 3Tubulincancercytostatic compound.epigeneticseurochevalierineHDACnatural compoundsirtuin inhibitor

Identifiers

PMID29401749
PMCPMC6017873
OpenAlexW2790171890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.